Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KINE-101 in Corticosteroid-Refractory CIDP
NCT07343310Phase 1Completed
- Sponsor
- KINE SCIENCES
- Start
- Aug 2024
- Primary completion
- Apr 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KINE-101 in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by KINE SCIENCES. Primary endpoints: Adverse Events, Clinically Significant Abnormal Hematology and 5 more. Started Aug 2024; status: completed.
02
Drugs
KINE-101
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT07343310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07343310.